Investor Relations LatestPress Releases Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide May 25, 2023 Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023 May 09, 2023 Theratechnologies Reports on its Annual Meeting of Shareholders btn News IR View All RecentEvents Jun 13, 2023 13 Jun 2023 at 10:00 AM EDT Oncology Investigator Call for Investors & Analysts: Phase 1 Trial Update Listen to Webcast Add to Outlook Add to Google Calendar May 09, 2023 09 May 2023 at 10:00 AM EDT Annual Meeting of Shareholders Listen to Webcast Apr 12, 2023 12 Apr 2023 at 8:30 AM EDT First-Quarter Fiscal 2023 Financial Results Conference Call Listen to Webcast btn Events View All Financial InformationLatest Earnings Show all Q1 2023 Financial Statement 1.1 MB MD&A 470.6 KB btn QRs View More PresentationsInvestor Presentation Download PDF
Jun 02, 2023 Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
May 25, 2023 Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
Jun 13, 2023 13 Jun 2023 at 10:00 AM EDT Oncology Investigator Call for Investors & Analysts: Phase 1 Trial Update Listen to Webcast Add to Outlook Add to Google Calendar
Apr 12, 2023 12 Apr 2023 at 8:30 AM EDT First-Quarter Fiscal 2023 Financial Results Conference Call Listen to Webcast